PECAM1 and cancer: Some affected pathways include IL-4 and IL-3 signaling (JAK3- and I-1A-upregulated), IL-10 signaling (IL-1A-upregulated), malaria infection (PECAM1-upregulated), inflammatory bowel disease (IL-1A-upregulated), pathways in cancer (JAK3- and RUNX1T1-upregulated), and JAK-STAT signaling pathway (JAK3-upregulated) (Figure 7B).